Sky Labs Showcases 'CART BP pro'
Analysis based on 8 articles · First reported Jul 03, 2026 · Last updated Jul 03, 2026
The showcase of 'CART BP pro' by Sky Labs at a global summit could lead to increased adoption of its technology by pharmaceutical companies, potentially boosting Sky Labs' valuation and market share in the digital health and medical device sectors. The validation and insurance coverage in South Korea further solidify its market position and could serve as a model for international expansion. This event highlights a shift towards more comfortable and efficient patient monitoring in clinical trials, which could benefit the broader pharmaceutical industry by reducing costs and accelerating drug development timelines.
Sky Labs introduced its 'CART BP pro', a ring-type cuffless blood pressure monitor, as a data platform for clinical trials and Real-World Evidence (RWE) at the 9th Digital Biomarkers in Clinical Trials Summit in Basel, Switzerland. The company aims to partner with global pharmaceutical companies by providing high-quality vital signs data. 'CART BP pro' addresses limitations of conventional cuff-type devices by offering comfortable, continuous blood pressure monitoring, which can reduce dropout rates and costs in clinical trials. The device is already validated in South Korea through adoption by the National Institutes of Health (NIH) and United States — Centers for Disease Control and Prevention (KDCA) for a large-scale cohort study, covered by national health insurance, and recommended by the Korean Society of Hypertension (KSH) guidelines. Jack Byung-hwan Lee, CEO of Sky Labs, expressed intentions to expand clinical trial use cases through strategic collaborations.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard